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Abstract
Mutations in RAD51D have been associated with an increased risk of hereditary ovarian cancer and although they have been
observed in the context of breast and ovarian cancer families, the association with breast cancer is unclear. The aim of this
current study was to validate the reported association of RAD51D with ovarian cancer and assess for an association with
breast cancer. We screened for RAD51D mutations in BRCA1/2mutation-negative index cases from 1,060 familial breast and/
or ovarian cancer families (including 741 affected by breast cancer only) and in 245 unselected ovarian cancer cases. Exons
containing novel non-synonymous variants were screened in 466 controls. Two overtly deleterious RAD51D mutations were
identified among the unselected ovarian cancers cases (0.82%) but none were detected among the 1,060 families. Our data
provide additional evidence that RAD51D mutations are enriched among ovarian cancer patients, but are extremely rare
among familial breast cancer patients.
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Introduction
RAD51 homolog D (S. cerevisiae) (RAD51D/RAD51L3;
MIM#602954) is a component of the homologous recombination
DNA repair pathway. The RAD51D protein forms a protein
complex with RAD51B, RAD51C and XRCC2 that binds to
single stranded DNA (including single stranded gaps in double
stranded DNA) and is required for the formation of RAD51 foci in
response to DNA damage [1,2]. Loveday et al [3] recently
reported the identification of eight truncating mutations in
RAD51D among 911 families with histories of breast and ovarian
cancer, compared to one mutation among 1,060 population
controls. They reported a significantly elevated risk of ovarian
cancer (6.30, 95% CI 2.86–13.85) but did not detect a significantly
elevated risk of breast cancer (1.32, 95% CI 0.59–2.96). They also
reported that mutations are more prevalent in multiple case
ovarian cancer families. RAD51D has subsequently been investi-
gated in an additional series of 175 breast and ovarian cancer
families, with an additional mutation being identified among the
51 families with at least two ovarian cancers (and among the 75
probands affected by ovarian cancer) [4]. Similarly, Pelttari et al
[5] identified a splice site mutation (c.576+1G) in two breast
cancer affected probands from 95 Finnish breast and/or ovarian
cancer families. Pelttari et al then screened for the c.576+1G
variant in an additional 2,200 breast and 553 ovarian cancer
patients and overall identified 5/707 patients with a personal or
family history of ovarian cancer compared to 2/2,105 breast
cancer only patients/families.
Until recently, BRCA1 and BRCA2 were the only genes known
to confer a considerable risk of ovarian cancer (in conjunction with
breast cancer) with two recent studies reporting that 13.3–14.1%
of unselected high grade ovarian cancers are accounted for by
mutations in one of these two genes [6,7]. A further small
proportion of unselected cases carry mutations in RAD51C [8,9].
Loveday et al [3] estimated that 0.6% of unselected ovarian cancer
cases will carry RAD51D mutations. To validate the association of
RAD51D mutations to ovarian cancer and assess if there is any risk
for breast cancer risk, we screened all coding exons in germline
DNA from an unselected cohort of 245 unselected ovarian cancer
patients and BRCA1/2-unrelated index cases from 1,060 breast
and/or ovarian cancer families. Exons containing novel, non-
synonymous variants among these cases were screened in a panel
of 466 cancer-naive control samples.
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e54772
Materials and Methods
The unselected ovarian cancer cohort included 245 individuals
with various histological subtypes of ovarian cancer (130 serous, 73
endometrioid, 35 mucinous, two clear cell, two granulosa cell
tumours, two adenocarcinomas and one mixed mullerian tumour).
These samples were obtained from patients presenting to hospitals
in the south of England, UK [10]. Undocumented, verbal consent
was obtained from patients as approved by the governing ethics
committee at the time.
The familial cohort included 540 individuals with verified
personal and family histories of breast and/or ovarian cancer who
were previously assessed at the Peter MacCallum Cancer Centre
Familial Cancer Centre (Australia), as well as index cases from 520
multiple case breast cancer families (with or without ovarian
cancer) obtained from the Kathleen Cunningham Foundation
Consortium for Research into Familial Breast Cancer (kConFab)
[11]. kConFab families are recruited through Familial Cancer
Centres throughout Australia and New Zealand. All families were
recruited based on multiple affected, mutigenerational family and
personal history of breast and/or ovarian cancer. The families
fulfilled diagnostic criteria for BRCA testing, with no underlying
BRCA1 or BRCA2 mutation having been identified. The ethnicity
of the index cases was self-reported as Caucasian in the vast
majority of cases. All individuals provided written, informed
consent for genetic testing of the genetic causes of hereditary
breast and ovarian cancer and subsequently tested negative for
mutations in BRCA1 and BRCA2. This study was approved by the
Peter MacCallum Cancer Centre Human Research Ethics
Committee. In total, index cases from 1,060 families were
examined in this study, including 16 with a family history of
ovarian cancer only, and 303 with a family history of both breast
and ovarian cancer. Of these index cases, 98 had a personal
history of ovarian cancer. The remaining 741 families had a
personal and family history of breast cancer only.
Cancer-naive control DNA samples were obtained from
kConFab (231 age- and ethnicity-matched best friend controls)
and from the Princess Anne Hospital, UK (235 Caucasian female
volunteers, as described previously) [12]. kConFab control
individuals provided written, informed consent. Controls from
the Princess Anne Hospital provided undocumented, verbal
consent as approved by the governing ethics committee at the
time.
DNA for mutation screening underwent whole genome
amplification (WGA) using the Repli-G amplification system
(Qiagen). Ten primer pairs were designed to amplify the ten
coding exons of RAD51D with amplicons ranging in size from
215–277 bp for high resolution melt (HRM) analysis (Table 1).
HRM analysis and DNA resequencing were performed as
described previously [13]. Variant positions were determined with
reference to GenBank reference sequence NM_002878.3. Nucle-
Table 1. Primers used for mutation analysis of RAD51D.
Primer pair Forward primer (59-39) Reverse primer (59-39)
Product
size (bp)
Annealing
temperature (6C)
RAD51D_ex1 CCGCGAATGCCCACGTGA AGGTATGCCAGGGCAGTG 228 62
RAD51D_ex2 GGGTAGAATTGACACCCCATT CTCCCAAAGTGCTGGGATTA 264 62
RAD51D_ex3 GGTGAATGACACCCTGGGA AGCATCAAAAGCAGAGCTGAG 241 62
RAD51D_ex4 CAGAACCAGTGCTTGAAAGAAA CCCTGGGCTATGCATCTACC 248 62
RAD51D_ex5 GAATCTGGGCAAGGTTTGGT GGGGTTTTCCTGTGTCAGAA 266 62
RAD51D_ex6 TCTTCCTTCTCAGCCTTACC ATTGCACATCTGCATTTCCA 277 62
RAD51D_ex7 TGTGTCCTAGAGGCTGACAGG GCCAGAGACCAGACTCCAGA 215 62
RAD51D_ex8 CCAGCTCTGGAGTCTGGTCT TTTGGGGTTCAGAAGCTGAC 239 62
RAD51D_ex9 CGATGTCCTCTATACTAGCA CCTCCAGGGCCCAAGATT 261 62
RAD51D_ex10 GAGGCTGAAACCTTGCAACT AGTGCCAGGTGGCAGTAAAC 253 62
doi:10.1371/journal.pone.0054772.t001
Figure 1. Loss of heterozygosity analysis of the c.556C.T
(p.(Arg186*)) variant. Sequencing (forward and reverse) of the
heterozygous c.556C.T variant in the germline sample, and tumour
DNA showing loss of the wildtype allele (with some contamination from
normal DNA).
doi:10.1371/journal.pone.0054772.g001
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otide numbering reflects cDNA numbering with +1 corresponding
to the A of the ATG translation initiation codon in the reference
sequence, according to HGVS guidelines (www.hgvs.org/
mutnomen). All novel variants were verified by Sanger resequen-
cing of non-WGA DNA. Tumour cells were needle dissected from
10 mm sections to obtain tumour DNA, which was subsequently
whole genome amplified.
The following in silico prediction tools were used to assess the
likely functional effect of the missense variants identified in this
study: PolyPhen-2 [14], SNPs&Go [15], MutPred [16], PMut [17]
and MutationTaster [18]. Human Splicing Finder (HSF) was used
to assess the effect of all non-truncating variants on splice sites
[19].
Results and Discussion
Two previously reported truncating mutations, p.(Arg186*) and
p.(Trp268*) were identified among a series of 245 unselected
ovarian cancer patients (0.82%). The p.(Arg186*) variant was
detected in a patient diagnosed with a grade 2 papillary serous
cystadenocarcinoma at 66 years of age. DNA sequence analysis of
tumour tissue obtained from this tumour showed reduction of the
wildtype allele consistent with loss of heterozygosity (LOH)
(Figure 1). The p.(Trp268*) variant was detected in a patient
diagnosed with an endometrioid carcinoma (no grade information)
at 70 years of age. No tumour tissue was available for LOH
analysis. No family history information is available from either
case. The histology of the two ovarian cases with truncating
RAD51D mutations (i.e. high grade serous and endometrioid) is
consistent with the majority of mutations reported in other
RAD51D studies [3,4,5,20], and with other ovarian cancers
associated with mutations in double strand break DNA repair
genes (e.g. BRCA1 and BRCA2), but the number of mutations in
RAD51D identified to date is too few to determine the significance
of this observation. A third truncating mutation, p.(Lys91Ilefs*13),
was identified in one of 466 control samples (0.21%). All three of
these mutations have previously been reported [3,4]. Table 2
provides a summary of all detected variants.
Analysis of 1,060 index cases from breast and/or ovarian cancer
families did not identify any further truncating mutations.
Interestingly, five rare (i.e. allele frequency ,1%) nonsynonymous
variants were detected, once each among 741 breast only cancer
families. Three of these variants were novel: p.(Met16Thr),
p.(Gly96Cys) and p.(Arg266Cys); the remaining two variants,
rs150498754 and rs140285068, are reported in the Exome
Variant Server (EVS) database at frequencies of ,0.02%. In silico
analysis tools predicted that variants p.(Gly96Cys) and
p.(Arg266Cys) would likely affect protein function (Table 2). Four
of eight synonymous or intronic variants detected were novel;
these were observed once each in either cases (c.117A.T,
c.-39C.T, c.264-6C.T) or controls (c.82+60C.T). None of
the synonymous or intronic variants were predicted to alter
splicing.
The frequency of truncating germline RAD51D mutations
detected in all patients with a personal history of ovarian cancer
in this study (2/343= 0.58%) is in keeping with that (0.6%)
estimated by Loveday et al., and higher than observed in controls
(0.21%). However, it is possible that the variant frequency
reported here could be an underestimate due to the reduced
sensitivity of HRM analysis compared to direct resequencing (used
by Loveday et al.). Five of the variants detected in this study have
previously been reported in RAD51D mutation studies by Loveday
et al. or Osher et al. [3,4], and may represent founder mutations.
However, there is no overlap with variants reported in more recent
studies by Pelttari et al. or Wickramanyake et al. [5,20]. To date,
no truncating mutations have been detected among 1,092
individuals in the 1000 genomes cohort (data release 20110521
v3) [21] or 5,379 individuals in the Exome Variant Server (release
ESP5400; NHLBI Exome Sequencing Project (ESP), Seattle, WA
(http://evs.gs.washington.edu/EVS/) [June 2012]).
The absence of truncating mutations in 741 breast cancer only
families (or 962 breast cancer-affected probands) provides further
evidence that RAD51D mutations do not contribute significantly to
breast cancer risk.
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